Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 24th Preview)
-
Regulatory approvals
The FDA cleared Gilead’s hepatitis D therapy Hepcludex (bulevirtide) four years after the agency previously rejected the drug tied to manufacturing and distribution issues. The approval gives clinicians a new option for chronic hepatitis D, where treatment choices have been limited and unmet need remains high. The decision follows a period of regulatory review that centered on the drug’s production and logistics—areas the FDA had flagged in its earlier refusal. With US authorization now in place, Gilead can move into expanded commercialization and broader prescribing for eligible patients. For the biotech industry, the approval reinforces how late-stage manufacturing remediation can be decisive for antiviral asset timelines, particularly in markets where follow-on options are constrained.
-
Oncology pipeline readouts and trial updates
ASCO will highlight a wave of pancreatic cancer innovation beyond KRAS, with daraxonrasib’s new data expected to anchor attention. Abstract coverage also points to multiple mechanism classes, including antibody-drug conjugates, bispecifics, and diagnostics aimed at improving patient selection and outcomes. The focus on post-KRAS strategies underscores how companies are reframing clinical development around actionable biology rather than single-pathway dependence. For investors and trial operators, the meeting preview signals where near-term trial readouts and competitive differentiation could concentrate. The 2026 agenda also suggests a broader trial design push—pairing targeted agents with biomarker-enriched populations and companion diagnostics—consistent with how pancreatic programs are increasingly structured.
-
Late-stage efficacy signals in solid tumors
A phase 3 ENGOT-ENG-NSGO/GOG-3031/RUBY update showed durable disease control with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer. At a median follow-up of 55.6 months, 4-year progression-free survival reached 57.9% with dostarlimab versus 15.7% with chemotherapy alone. Mixture cure modeling in the abstract estimated that 54% of patients had potential curative benefit with the combination regimen. Updated OS results were also included, with a reported median OS of 44.6 months versus 28.2 months for chemotherapy alone (HR 0.69). The readout, expected to shape discussions for ASCO 2026, elevates the chance that the therapy could become a key option for biomarker-defined patients where durability has historically been difficult to achieve.
-
Adc approval in breast cancer
The FDA approved datopotamab deruxtecan (Dato-DXd; Datroway) for unresectable or metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval is based on phase 3 TROPION-Breast02 results showing overall survival benefit over investigator’s choice of chemotherapy. In the trial, median OS was 23.7 months with Dato-DXd versus 18.7 months with chemotherapy (HR 0.79; P=.0290). The update also reported a 43% reduction in risk of progression or death (HR 0.57) and higher objective response rate (64% versus 30%). For oncology development, the label supports an expanded first-line TROP2-directed ADC option in a biologically and clinically challenging subset of TNBC.
-
Gene editing clinical expansion and scientific framing
A University of Pennsylvania and Children’s Hospital of Philadelphia case study highlighted meaningful clinical benefits from an mRNA-based CRISPR base-editing approach in an infant with CPS1 deficiency, but the lead scientist emphasized it was not a traditional cure campaign. Investigators reported that the patient can eat a normal protein-filled diet, with the goal of delaying liver transplant until later. In comments tied to the reported outcomes, Penn’s Kiran Musunuru argued the intervention was an expanded-access IND clinical-care effort rather than a clinical trial or research program, calling it “unambiguously not a cure.” He framed the work as a demonstration of feasibility that has helped accelerate the broader push to get base editing into clinical development. The case also points to ongoing competition in base editing programs, with companies such as Verve Therapeutics and YolTech Therapeutics pursuing their own clinical trajectories.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.